Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Phase 3

Completed

• Conditions: Diabetes; Diabetes Mellitus, Type 2
• Interventions: Drug: insulin degludec; Drug: insulin glargine

• Registration Number: NCT01076647
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This trial was conducted in Europe and North America. The aim of this clinical trial was to compare NN1250 (insulin degludec (IDeg)), a soluble insulin basal analogue (SIBA), with insulin glargine (IGlar), as add-on to subject's ongoing treatment with metformin and/or DPP-4 (dipeptyl peptidase 4) inhibitors, in patients with type 2 diabetes being treated with oral anti-diabetic drugs (OADs).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-02-25
• Study First Submitted QC: 2010-02-25
• Study First Posted: 2010-02-26
• Study Start: 2010-03
• Primary Completion: 2010-12
• Study Completion: 2010-12
• Disposition First Submitted: 2011-02-23
• Disposition First Submitted QC: 2011-02-23
• Disposition First Posted: 2011-03-01
• Results First Submitted: 2015-10-13
• Results First Submitted QC: 2015-10-13
• Results First Posted: 2015-11-10
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-20
• Last Update Posted: 2017-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 467

Inclusion Criteria

• Type 2 diabetes (diagnosed clinically) for at least 6 months
• Insulin naïve subjects (allowed are: previous short term insulin treatment up to 14 days; treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days)
• Current treatment: metformin monotherapy or metformin in any combination with insulin secretagogues (sulphonylurea (SU) or glinide), DPP-4 inhibitor, alpha-glucosidase-inhibitor (acarbose) with unchanged dosing for at least 3 months prior to visit 1 with the minimum doses stated: -Metformin: alone or in combination (including fixed combination) 1500 mg daily or maximum tolerated dose (at least 1000 mg daily)-Insulin secretagogue (sulfonylurea (SU) or glinide): minimum half of the daily maximal dose according to local labelling -DPP-4 inhibitor: minimum half of the daily maximal dose according to local labelling -alpha-glucosidase-inhibitor (acarbose): minimum half of the daily maximal dose or maximum tolerated dose
• HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis
• BMI (Body Mass Index) below or equal to 45.0 kg/m^2

Exclusion Criteria

• Use within the last 3 months prior to Visit 1 of: Thiazoledinediones (TZDs), Exenatide or Liraglutide
• Cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
• Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)
• Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements
• Cancer and medical history of cancer hereof (except basal cell skin cancer or squamous cell skin cancer)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IDeg 3TW	insulin degludec	-
IGlar OD	insulin glargine	-

Primary Outcome Measures

Name	Time	Method
Change in Glycosylated Haemoglobin (HbA1c)	Week 0, Week 26	Change from baseline in HbA1c after 26 weeks of treatment

Secondary Outcome Measures

Name	Time	Method
Change in Body Weight	Week 0, Week 26	Change from baseline in body weight after 26 weeks of treatment

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇷🇴 Satu Mare, Romania